Abstract Search

ea0029p1408 | Pituitary Clinical | ICEECE2012

Pasireotide treatment is associated with clinically meaningful improvements in health-related quality of life in Cushing’s disease: results from a large, randomized, double-blind phase III trial

Webb S , Badia X , Zgliczynski W , Portocarrero-Ortiz L , Maldonado M , Trovato A , Forsythe A , Nelson L , McLeod L , De Block C , Gadelha M

Introduction: Patients with Cushings disease have significantly impaired health-related quality of life (HRQoL). Effective treatment is needed to treat Cushings disease and improve HRQoL; however, there are currently no approved medical treatments for Cushings disease. The effect of pasireotide on HRQoL in patients with Cushings disease was evaluated as part of a randomized, phase III study.Methods: Patients with persistent/recurr...

0 shares

Endocrine Abstracts

Pasireotide treatment is associated with clinically meaningful improvements in health-related quality of life in Cushing’s disease: results from a large, randomized, double-blind phase III trial

BiosciAbstracts